

# A systems approach identifies HIPK2 as a key regulator

Nature Medicine

18, 580-588

DOI: [10.1038/nm.2685](https://doi.org/10.1038/nm.2685)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Fibrogenic cell reversion underlies fibrosis regression in liver. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9230-9231.	3.3	44
2	New target in kidney fibrosis identified by systems approach. Nature Reviews Nephrology, 2012, 8, 254-254.	4.1	0
3	Posttranslational modifications regulate HIPK2, a driver of proliferative diseases. Journal of Molecular Medicine, 2013, 91, 1051-1058.	1.7	38
4	The primary glomerulonephritides: a systems biology approach. Nature Reviews Nephrology, 2013, 9, 500-512.	4.1	21
5	Vascular Complications of Diabetes: Mechanisms of Injury and Protective Factors. Cell Metabolism, 2013, 17, 20-33.	7.2	590
6	Therapy for Fibrotic Diseases: Nearing the Starting Line. Science Translational Medicine, 2013, 5, 167sr1.	5.8	546
7	Molecular targets for treatment of kidney fibrosis. Journal of Molecular Medicine, 2013, 91, 549-559.	1.7	71
8	Targeting the epithelial cells in fibrosis: a new concept for an old disease. Drug Discovery Today, 2013, 18, 582-591.	3.2	9
9	The role of promoter hypermethylation in fibroblast activation and fibrogenesis. Journal of Pathology, 2013, 229, 264-273.	2.1	81
10	Toward a systems-level understanding of the Hedgehog signaling pathway: defining the complex, robust, and fragile. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 83-100.	6.6	9
11	Rapamycin-induced modulation of miRNA expression is associated with amelioration of HIV-associated nephropathy (HIVAN). Experimental Cell Research, 2013, 319, 2073-2080.	1.2	16
12	MicroRNAs in HIV-associated nephropathy (HIVAN). Experimental and Molecular Pathology, 2013, 94, 65-72.	0.9	14
13	Progress in the development of animal models of acute kidney injury and its impact on drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 879-895.	2.5	28
14	Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase. Journal of the American Society of Nephrology: JASN, 2013, 24, 801-811.	3.0	46
15	Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4203-E4212.	3.3	42
16	Homeodomain-interacting protein kinase2 in human idiopathic pulmonary fibrosis. Journal of Cellular Physiology, 2013, 228, 235-241.	2.0	26
17	Activation of the Interleukin-4/Signal Transducer and Activator of Transcription 6 Signaling Pathway and Homeodomain-Interacting Protein Kinase 2 Production by Tonsillar Mononuclear Cells in IgA Nephropathy. American Journal of Nephrology, 2013, 38, 321-332.	1.4	27
18	Transcriptional Corepressors HIPK1 and HIPK2 Control Angiogenesis Via TGF- $\beta$ -TAK1-Dependent Mechanism. PLoS Biology, 2013, 11, e1001527.	2.6	50

#	ARTICLE	IF	CITATIONS
19	Homeodomain interacting protein kinase (HIPK1) is required in the soma for robust germline proliferation in <i>C. elegans</i> . <i>Developmental Dynamics</i> , 2013, 242, 1250-1261.	0.8	15
20	Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. <i>Aids</i> , 2013, 27, 1091-1098.	1.0	36
21	Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways. <i>Biomedical Research</i> , 2013, 34, 309-319.	0.3	22
22	A Bioinformatics Approach Identifies Signal Transducer and Activator of Transcription-3 and Checkpoint Kinase 1 as Upstream Regulators of Kidney Injury Molecule-1 after Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 105-118.	3.0	57
23	Role of HIPK2 in kidney fibrosis. <i>Kidney International Supplements</i> , 2014, 4, 97-101.	4.6	26
24	How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 972-980.	0.4	13
25	Induction of Retinol Dehydrogenase 9 Expression in Podocytes Attenuates Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1933-1941.	3.0	14
26	HIPK2 modification code for cell death and survival. <i>Molecular and Cellular Oncology</i> , 2014, 1, e955999.	0.3	18
27	Advances in the pathogenesis of HIV-associated kidney diseases. <i>Kidney International</i> , 2014, 86, 266-274.	2.6	46
28	Unilateral ureteral obstruction: beyond obstruction. <i>International Urology and Nephrology</i> , 2014, 46, 765-776.	0.6	157
29	Metabolomics-proteomics profiles delineate metabolic changes in kidney fibrosis disease. <i>Proteomics</i> , 2015, 15, 3699-3710.	1.3	31
30	Nodes with high centrality in protein interaction networks are responsible for driving signaling pathways in diabetic nephropathy. <i>PeerJ</i> , 2015, 3, e1284.	0.9	38
31	Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF- $\beta$ 2-Induced Epithelial-Mesenchymal Transition. <i>PLoS ONE</i> , 2015, 10, e0117757.	1.1	24
32	HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease. <i>Frontiers in Physiology</i> , 2015, 6, 132.	1.3	21
33	WSB1 promotes tumor metastasis by inducing pVHL degradation. <i>Genes and Development</i> , 2015, 29, 2244-2257.	2.7	52
34	miR-141 regulates TGF- $\beta$ 21-induced epithelial-mesenchymal transition through repression of HIPK2 expression in renal tubular epithelial cells. <i>International Journal of Molecular Medicine</i> , 2015, 35, 311-318.	1.8	70
35	Mechanisms of initiation and progression of intestinal fibrosis in IBD. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 53-65.	0.6	126
36	Activation of non-canonical TGF- $\beta$ 21 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 234-241.	0.6	31

#	ARTICLE	IF	CITATIONS
37	Proteomic biomarkers in kidney disease: issues in development and implementation. <i>Nature Reviews Nephrology</i> , 2015, 11, 221-232.	4.1	101
38	Effects of cell-type-specific expression of a pan-caspase inhibitor on renal fibrogenesis. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 350-358.	0.7	3
39	Renal Allograft Fibrosis: Biology and Therapeutic Targets. <i>American Journal of Transplantation</i> , 2015, 15, 863-886.	2.6	81
40	RTN1 mediates progression of kidney disease by inducing ER stress. <i>Nature Communications</i> , 2015, 6, 7841.	5.8	80
41	MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. <i>Annals of the New York Academy of Sciences</i> , 2015, 1353, 72-88.	1.8	137
42	Body fluid peptide and protein signatures in diabetic kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv43-iv53.	0.4	7
43	Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 693-720.	21.5	181
44	Defining nephrotic syndrome from an integrative genomics perspective. <i>Pediatric Nephrology</i> , 2015, 30, 51-63.	0.9	23
45	Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy. <i>Scientific Reports</i> , 2016, 6, 38789.	1.6	40
46	Transforming growth factor $\beta$ 2-related genes in human retinal pigment epithelial cells after tacrolimus treatment. <i>Pharmacological Reports</i> , 2016, 68, 969-974.	1.5	5
47	Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4976-4981.	3.3	249
48	A high affinity kidney targeting by chitobionic acid-conjugated polysorbitol gene transporter alleviates unilateral ureteral obstruction in rats. <i>Biomaterials</i> , 2016, 102, 43-57.	5.7	7
49	Hypoxia: The Force that Drives Chronic Kidney Disease. <i>Clinical Medicine and Research</i> , 2016, 14, 15-39.	0.4	115
50	A Novel Inhibitor of Homeodomain Interacting Protein Kinase 2 Mitigates Kidney Fibrosis through Inhibition of the TGF- $\beta$ 1/Smad3 Pathway. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2133-2143.	3.0	43
51	A metabolite-GWAS (mGWAS) approach to unveil chronic kidney disease progression. <i>Kidney International</i> , 2017, 91, 1274-1276.	2.6	11
52	Knockdown of HIPK2 attenuates the pro-fibrogenic response of hepatic stellate cells induced by TGF- $\beta$ 1. <i>Biomedicine and Pharmacotherapy</i> , 2017, 85, 575-581.	2.5	12
53	The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression. <i>Kidney International</i> , 2017, 92, 612-624.	2.6	36
54	Role of Homeodomain-Interacting Protein Kinase 2 in the Pathogenesis of Tissue Fibrosis in Keloid-Derived Keratinocytes. <i>Annals of Plastic Surgery</i> , 2017, 79, 546-551.	0.5	10

#	ARTICLE	IF	CITATIONS
55	Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. <i>Oncogene</i> , 2017, 36, 6204-6212.	2.6	75
56	Homeodomain interacting protein kinase promotes tumorigenesis and metastatic cell behavior. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	20
57	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4343-4410.	1.8	323
58	HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 1113-1118.	0.8	10
59	Homeodomain-Interacting Protein Kinases. <i>Current Topics in Developmental Biology</i> , 2017, 123, 73-103.	1.0	56
60	HIPK2 polymorphisms rs2058265, rs6464214, and rs7456421 were associated with kidney stone disease in Chinese males not females. <i>Gene</i> , 2018, 653, 51-56.	1.0	8
61	Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/ $\beta$ -Catenin Pathway and Targeted Phosphorylation of smad3 Signaling. <i>Journal of Agricultural and Food Chemistry</i> , 2018, 66, 1828-1842.	2.4	115
62	PGC-1 $\beta$ ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism. <i>Molecular Medicine Reports</i> , 2018, 17, 4490-4498.	1.1	35
63	Central role of dysregulation of TGF- $\beta$ 2/Smad in CKD progression and potential targets of its treatment. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 670-681.	2.5	250
64	Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease. <i>Kidney Research and Clinical Practice</i> , 2018, 37, 197-209.	0.9	47
65	Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by microRNAs. <i>MicroRNA (Shariqah)</i> , Tj ETQq0,0 0 rgBT, Overlock : 0.6 31	0.6	31
66	Targeting TGF- $\beta$ 2 Signaling in Kidney Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2532.	1.8	164
67	eXpression2Kinases (X2K) Web: linking expression signatures to upstream cell signaling networks. <i>Nucleic Acids Research</i> , 2018, 46, W171-W179.	6.5	127
68	A dual role of miR-22 in rhabdomyolysis-induced acute kidney injury. <i>Acta Physiologica</i> , 2018, 224, e13102.	1.8	12
69	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2018, , 1-42.	0.1	0
70	Molecular Mechanisms of Injury in HIV-Associated Nephropathy. <i>Frontiers in Medicine</i> , 2018, 5, 177.	1.2	26
71	Cellular and molecular mechanisms of kidney fibrosis. <i>Molecular Aspects of Medicine</i> , 2019, 65, 16-36.	2.7	289
72	Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer. <i>Briefings in Bioinformatics</i> , 2019, 20, 717-731.	3.2	20

#	ARTICLE	IF	CITATIONS
73	IRF6 and TAK1 coordinately promote the activation of HIPK2 to stimulate apoptosis during palate fusion. <i>Science Signaling</i> , 2019, 12, .	1.6	12
74	The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. <i>Journal of Biological Chemistry</i> , 2019, 294, 13545-13559.	1.6	22
75	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. <i>Experimental Hematology</i> , 2019, 79, 16-25.e3.	0.2	8
76	Cardiomyocyte Homeodomain-Interacting Protein Kinase 2 Maintains Basal Cardiac Function via Extracellular Signal-Regulated Kinase Signaling. <i>Circulation</i> , 2019, 140, 1820-1833.	1.6	21
77	EGFR drives the progression of AKI to CKD through HIPK2 overexpression. <i>Theranostics</i> , 2019, 9, 2712-2726.	4.6	61
78	Identification of microRNA-mRNA networks involved in cisplatin-induced renal tubular epithelial cells injury. <i>European Journal of Pharmacology</i> , 2019, 851, 1-12.	1.7	18
79	Impact of genetic variant of HIPK2 on the risk of severe radiation pneumonitis in lung cancer patients treated with radiation therapy. <i>Radiation Oncology</i> , 2020, 15, 9.	1.2	13
80	HIPK2 overexpression relieves hypoxia/reoxygenation-induced apoptosis and oxidative damage of cardiomyocytes through enhancement of the Nrf2/ARE signaling pathway. <i>Chemico-Biological Interactions</i> , 2020, 316, 108922.	1.7	16
81	Novel targets to cure primary myelofibrosis from studies on <i>Gata1</i> <sup>low</sup> mice. <i>IUBMB Life</i> , 2020, 72, 131-141.	1.5	5
82	Genome-Wide Characterization of Host Transcriptional and Epigenetic Alterations During HIV Infection of T Lymphocytes. <i>Frontiers in Immunology</i> , 2020, 11, 2131.	2.2	6
83	Role of SIRT1 in HIV-associated kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F335-F344.	1.3	13
84	Multi-scale models of lung fibrosis. <i>Matrix Biology</i> , 2020, 91-92, 35-50.	1.5	15
85	Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ Repair. <i>Developmental Cell</i> , 2020, 53, 677-690.e4.	3.1	25
86	Sequential Wnt Agonist Then Antagonist Treatment Accelerates Tissue Repair and Minimizes Fibrosis. <i>IScience</i> , 2020, 23, 101047.	1.9	9
87	An Alternative Splice Variant of HIPK2 with Intron Retention Contributes to Cytokinesis. <i>Cells</i> , 2020, 9, 484.	1.8	13
88	Glomerular Transcriptome Profiles in Focal Glomerulosclerosis: New Genes and Pathways for Steroid Resistance. <i>American Journal of Nephrology</i> , 2020, 51, 442-452.	1.4	6
89	The nutrient sensor OGT regulates Hipk stability and tumorigenic-like activities in <i>Drosophila</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2004-2013.	3.3	19
90	Bioinformatics toolbox for exploring protein phosphorylation network. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	7

#	ARTICLE	IF	CITATIONS
91	Amygdalin alleviates renal injury by suppressing inflammation, oxidative stress and fibrosis in streptozotocin-induced diabetic rats. <i>Life Sciences</i> , 2021, 265, 118835.	2.0	21
92	Diabetic fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166044.	1.8	81
93	HIPK2 phosphorylates HDAC3 for NF- $\kappa$ B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	23
94	Inhibition of HIPK2 Alleviates Thoracic Aortic Disease in Mice With Progressively Severe Marfan Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2483-2493.	1.1	4
95	Tubular HIPK2 is a key contributor to renal fibrosis. <i>JCI Insight</i> , 2020, 5, .	2.3	14
96	Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 208-221.	3.9	62
97	TSS-Seq analysis of low pH-induced gene expression in intercalated cells in the renal collecting duct. <i>PLoS ONE</i> , 2017, 12, e0184185.	1.1	4
98	Exosomal miR-19a from adipose-derived stem cells suppresses differentiation of corneal keratocytes into myofibroblasts. <i>Aging</i> , 2020, 12, 4093-4110.	1.4	13
99	Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies. <i>Oncotarget</i> , 2017, 8, 20452-20461.	0.8	48
100	Multistep virtual screening based identification of homeodomain-interacting protein kinase 2 inhibitors: An opportunity for treating Chronic Kidney Disease. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2021, 219, 104440.	1.8	1
102	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2018, , 161-201.	0.1	0
103	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2019, , 1-41.	0.1	0
104	Perturbation of HSP Network in MCF-7 Breast Cancer Cell Line Triggers Inducible HSP70 Expression and Leads to Tumor Suppression. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1051-1060.	0.9	8
105	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2020, , 161-201.	0.1	0
106	Central Nodes in Protein Interaction Networks Drive Critical Functions in Transforming Growth Factor Beta-1 Stimulated Kidney Cells. <i>Cell Journal</i> , 2017, 18, 514-531.	0.2	7
107	HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression. <i>Molecular Cancer Research</i> , 2022, 20, 686-698.	1.5	5
108	MicroRNA-193b-3p reduces oxidative stress and mitochondrial damage in rats with cerebral ischemia-reperfusion injury via the seven in absentia homolog 1/Jun N-terminal kinase pathway. <i>Bioengineered</i> , 2022, 13, 6942-6954.	1.4	5
109	HIPK2 directs cell type-specific regulation of STAT3 transcriptional activity in Th17 cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117112119.	3.3	2

#	ARTICLE	IF	CITATIONS
114	Knockdown of HIPK2 attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	0.8	3
115	Identification of selective homeodomain interacting protein kinase 2 inhibitors, a potential treatment for renal fibrosis. <i>Bioorganic Chemistry</i> , 2022, 126, 105866.	2.0	3
116	Emerging role of tumor suppressor p53 in acute and chronic kidney diseases. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	16
117	SIRT6 overexpression retards renal interstitial fibrosis through targeting HIPK2 in chronic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
119	Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling. <i>EBioMedicine</i> , 2022, 85, 104274.	2.7	9
120	ASH2L Aggravates Fibrosis and Inflammation through HIPK2 in High Glucose-Induced Glomerular Mesangial Cells. <i>Genes</i> , 2022, 13, 2244.	1.0	5
121	Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis. <i>Progress in Retinal and Eye Research</i> , 2023, 94, 101151.	7.3	2
122	HIPK2 as a Novel Regulator of Fibrosis. <i>Cancers</i> , 2023, 15, 1059.	1.7	7
123	Low dose Taxol ameliorated renal fibrosis in mice with diabetic kidney disease by downregulation of HIPK2. <i>Life Sciences</i> , 2023, 320, 121540.	2.0	1
124	Recent advances in the development of HIPK2 inhibitors as anti-renal fibrosis agents. <i>Future Medicinal Chemistry</i> , 2023, 15, 453-465.	1.1	1